- Home
- CRF vs VIR Comparison
CRF vs VIR Comparison
Compare CRF & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | VIR |
|---|---|---|
| Founded | 1973 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRF | VIR |
|---|---|---|
| Price | $7.78 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.63 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 18.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | $11,461,786.00 | ★ $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.38 | ★ N/A |
| Revenue Growth | ★ 6.53 | N/A |
| 52 Week Low | $5.70 | $4.16 |
| 52 Week High | $9.56 | $10.67 |
Technical Indicators
Market Signals| Indicator | CRF | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 53.96 |
| Support Level | $7.65 | $6.86 |
| Resistance Level | $8.00 | $7.97 |
| Average True Range (ATR) | 0.09 | 0.50 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 31.17 | 64.40 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.